Longitudinal records are fragmented and cross-institutional
Clinical reports accumulate across time with missing data, uncertainty, and cross-centre inconsistency. Case context must be assembled before safe reasoning can begin.
OMGs
Ovarian tumour Multidisciplinary intelligent aGent System
Making ovarian tumour MDT expertise accessible where timely consensus is scarce.
Ovarian tumour management increasingly relies on multidisciplinary tumour board deliberation, yet timely expert consensus remains scarce in many centres. OMGs uses domain-specific agents to integrate multidisciplinary evidence and produce structured, traceable MDT-style recommendations.
Video
Watch OMGs in Action
See how OMGs supports ovarian tumour MDT decision-making.
Why OMGs
Built for multidisciplinary tumour board decisions across the care continuum.
OMGs is designed for fragmented records, role-specific MDT reasoning, and outputs that can be traced back to reports, guidelines, and literature.
Decision criteria change across the care continuum
Primary management, histology-led pathways, platinum-sensitive relapse, platinum-resistant relapse, and reassessment each require different evidence priorities.
Recommendations must remain traceable
Outputs need explicit grounding in guidelines, literature, and patient-specific reports, together with clear points for reassessment.
Longitudinal records are fragmented and cross-institutional
Clinical reports accumulate across time with missing data, uncertainty, and cross-centre inconsistency. Case context must be assembled before safe reasoning can begin.
Decision criteria change across the care continuum
Primary management, histology-led pathways, platinum-sensitive relapse, platinum-resistant relapse, and reassessment each require different evidence priorities.
Recommendations must remain traceable
Outputs need explicit grounding in guidelines, literature, and patient-specific reports, together with clear points for reassessment.
How It Works
From case assembly to multi-specialty MDT output.
OMGs brings case structuring, evidence retrieval, report selection, and five-specialty MDT deliberation into one visible workflow.
Rather than returning a single opaque answer, OMGs assembles case context, retrieves evidence, tracks provenance, and stages multi-round discussion among the chair, oncology, radiology, pathology, and nuclear medicine agents before producing a structured MDT recommendation.
Clinical inputs are assembled first
Structured EHR context, laboratory trends, imaging, pathology, genomics, and trial options are consolidated into a reasoning-ready patient view.
Five specialty agents keep the MDT logic explicit
The chair, oncologist, radiologist, pathologist, and nuclear medicine physician deliberate with evidence search, report selection, and provenance tracking before returning a plan.
Outputs stay structured and citable
The final result includes case core, timeline, specialty evidence, references, Final Assessment, Core Treatment Strategy, and Change Triggers.
Five Scenes
Five clinical scenes across the ovarian tumour care continuum.
Each scene represents a distinct decision setting, with different evidence priorities and intervention choices.
Primary management
What the MDT aims to decide
Clinical Validation
Validated across four study phases.
Evaluation spans retrospective benchmarking, re-MDT comparison, prospective comparison with routine MDT conclusions, and human-AI collaboration.
Phase I
Single-centre retrospective benchmarking against CHAIR-R, CHAIR-E, and CHAIR-D.
Highest mean SPEAR profilePhase II
Multicentre retrospective re-MDT evaluation with comparability to expert re-MDT.
4.45 vs 4.53 overallPhase III
Prospective multicentre comparison against routine MDT conclusions in real workflow.
59 prospective patientsPhase IV
Human-AI collaboration showing the strongest gains in Evidence and Robustness.
Clinician recommendations improved
OMGs Explore
How can OMGs help today?
Results